A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease
C. Lee (Yongin, Republic of Korea), D. Bae (Yongin, Republic of Korea), M. Cho (Yongin, Republic of Korea), S. Shin (Yongin, Republic of Korea), J. Kim (Yongin, Republic of Korea), J. Lee (Yongin, Republic of Korea), S. Kang (Yongin, Republic of Korea), J. Jung (Yongin, Republic of Korea), H. Koo (Yongin, Republic of Korea), J. Park (Yongin, Republic of Korea)
Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Lee (Yongin, Republic of Korea), D. Bae (Yongin, Republic of Korea), M. Cho (Yongin, Republic of Korea), S. Shin (Yongin, Republic of Korea), J. Kim (Yongin, Republic of Korea), J. Lee (Yongin, Republic of Korea), S. Kang (Yongin, Republic of Korea), J. Jung (Yongin, Republic of Korea), H. Koo (Yongin, Republic of Korea), J. Park (Yongin, Republic of Korea). A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease. 4241
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: